Anzeige
Mehr »
Login
Donnerstag, 30.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die neuen Aktien-Stars der nächsten Rallye-Stufe im Uransektor
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JKQ4 | ISIN: CA29668H7085 | Ticker-Symbol:
NASDAQ
30.05.24
17:40 Uhr
6,670 US-Dollar
+0,280
+4,38 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ESSA PHARMA INC Chart 1 Jahr
5-Tage-Chart
ESSA PHARMA INC 5-Tage-Chart

Aktuelle News zur ESSA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:17ESSA Pharma to Present at the Jefferies Global Healthcare Conference1
14.05.ESSA Pharma GAAP EPS of -$0.20 misses by $0.013
14.05.ESSA Pharma Inc. - 8-K, Current Report1
14.05.ESSA Pharma Inc. - 10-Q, Quarterly Report1
14.05.ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 202453Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens...
► Artikel lesen
09.04.ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference1
05.04.ESSA Pharma Inc. - S-8, Securities to be offered to employees in employee benefit plans-
08.03.Essa Pharma Inc. Reports Results Of Annual General Meeting Of Shareholders156SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing...
► Artikel lesen
07.03.ESSA Pharma Inc. - 8-K, Current Report1
13.02.ESSA Pharma: Q1 Earnings Insights1
13.02.ESSA Pharma GAAP EPS of -$0.141
13.02.ESSA Pharma Inc reports results for the quarter ended in December - Earnings Summary-
13.02.ESSA Pharma Inc. - 10-Q, Quarterly Report1
13.02.ESSA Pharma Inc. - 8-K, Current Report1
13.02.ESSA Pharma Inc: ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023246Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving...
► Artikel lesen
06.02.ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference-
29.01.ESSA Pharma Inc. - 8-K, Current Report2
26.01.What's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?4
25.01.ESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium880Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of...
► Artikel lesen
16.01.Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session2
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1